Quality of life of patients undergoing an allogeneic stem cell transplantation

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00003878

Enrollment

600

Registered

2012-06-01

Start date

2009-01-08

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematologic malignancies after hematopoietic stem cell transplantation

Interventions

Group 1: Patients with standard (traditional myeloablative) conditioning Group 2: Patients with reduced-intensity conditioning (RIC)

Eligibility

Sex/Gender

All

Age

19 Years to 99 Years

Inclusion criteria

Inclusion criteria: - all patients who will be treated with an allogeneic stem cell transplantation after conventional or reduced intensity conditioning - age = 18 years - able to understand the intention of the study aims and to give informed consent - able to understand and to complete the questionnaires

Exclusion criteria

Exclusion criteria: - patients younger than 18 years - lack of informed consent - patients who do not continue to the transplant - no MED A data submitted to the EBMT - patients transplanted for solid tumors - patients participating in another quality of life study during the same period of time

Design outcomes

Primary

Measure	Time frame
Assessment and comparison of the quality of life (EORTC QLQ-C30, EORTC QLQ-HDC29) after allogeneic stem cell transplantation with reduced intensity or conventional conditioning	—

Secondary

Measure	Time frame
Transplant related mortality; Overall survival; Event free survival; Graft versus host disease	—

Countries

France, Germany, Italy, Switzerland

Contacts

Public ContactJoachim Weis

Klinik für Tumorbiologie

weis@tumorbio.uni-freiburg.de+49 761 206 2220

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026